First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811 Journal Article


Authors: Chung, H. C.; Bang, Y. J.; Fuchs, C. S.; Qin, S. K.; Satoh, T.; Shitara, K.; Tabernero, J.; Cutsem, E. V.; Alsina, M.; Cao, Z. A.; Lu, J.; Bhagia, P.; Shih, C. S.; Janjigian, Y. Y.
Article Title: First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
Abstract: Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Clinical trial registration: NCT03615326 (ClinicalTrials.gov. © 2020 Future Medicine Ltd
Keywords: chemotherapy; trastuzumab; human epidermal growth factor receptor 2; first-line therapy; gastric cancer; gastroesophageal junction cancer; pembrolizumab
Journal Title: Future Oncology
Volume: 17
Issue: 5
ISSN: 1479-6694
Publisher: Future Medicine  
Date Published: 2021-02-01
Start Page: 491
End Page: 501
Language: English
DOI: 10.2217/fon-2020-0737
PUBMED: 33167735
PROVIDER: scopus
PMCID: PMC8411394
DOI/URL:
Notes: Article -- Export Date: 1 March 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yelena Yuriy Janjigian
    395 Janjigian